Searched for
ZINETAC
Ranitidine ban deferred despite cancer concernsDespite concerns about cancer-causing agents in Ranitidine and an expert panel's recommendation to suspend it, India's drug advisory body h...- GSK gets restraining order against Elder LaboratoriesGSK approached the high court against Elder Laboratories early this year for alleged infringement of trademark, including usage of identica...
- No plans to reintroduce Zinetac in India: GSKBritish drugmaker GSK said it has no plans to reintroduce its once top-selling heartburn medication Zinetac (ranitidine) brand in India, de...
- GSK's pharma brands doing well: India MDThe company is also banking on its dermatology portfolio - a segment where it leads the market with brands such as Betnovate, T-Bact and Te...
- GSK sends notices to Akums, Associate over 'Zinetac' brandThe Indian unit of British drugmaker GSK further alleged that Nicholas Healthcare and Akums are also using identical packaging to take adva...
- GlaxoSmithKline Pharma Q2 results: Net profit declines 85% to Rs 76 crConsolidated revenue from operations of the company stood at Rs 879.32 crore for the quarter under consideration. It was Rs 882.02 crore fo...
- Add GlaxoSmithKline Pharma, target price Rs 1,570: Centrum BrokingThe company’s strategy of focusing on core brands and vaccines is working well for the company, says the brokerage.
- Market Movers: Titan, Piramal see smart rally; 233 stocks turn bullishSensex advanced 917 points to 40,789 while its counterpart Nifty leaped 271 points to 11,979.
- GSK Pharma tumbles 12% after posting Rs 660-crore Q3 lossThe company's consolidated revenue from operations stood at Rs 778.59 crore for the quarter under consideration.
- Stocks in the news: TCS, Welspun Corp, PNB, Titan, Affle India and RILAffle posted a 31.3 per cent increase in consolidated net profit at Rs 21.4 crore for Q3
- Drug regulator steps up monitoring of ranitidineThe US FDA announced an update of testing of NDMA in ranitidine, warning manufacturers not to use a high-temperature test for NDMA as it ge...
- GSK to recall Ranitidine from India after regulator alertBritish drugmaker will suspend release, distribution and supply of the heartburn drug.
- GSK Pharma to invest Rs 1,000 crore in Karnataka plantWe are investing Rs 1,000 crore in a new state-of-the- art pharmaceutical factory in Vemgal, Karnataka. The factory will initially supply a...
- Get ready to cough up more for syrupThe drug controller has sought price details of 65 excipients used to make medicines, possibly to revise their prices that was last done in...
Load More
